RootsAnalysis has done a detailed study on RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus onsiRNA, miRNA, shRNA and DNA, covering key aspects of the industry’s evolutionand identifying potential future growth opportunities.
KeyMarket Insights
· Over 32,000 patents related to RNAitherapeutics, indicating the heightened pace of research, have been filed /granted in the last several years
· Presently, there is only one approved drugand over 150 product candidates, which are being evaluated for the treatment ofa variety of disease indications, based on the RNAi principle
· In order to achieve a competitive edge, thedrug developers are increasingly focusing on developing the robust pipelinemolecules across different therapeutic areas
· Majority of the candidate therapies arecurrently in the early stages of development and are based on the siRNAapproach; the innovation in this domain is being led by developers headquarteredin the US
· Several trials evaluating various RNAi drugcandidates against a wide range of therapeutic indications have been registeredin the recent past
· Investors, having realized the opportunitywithin this emerging segment of the pharmaceutical industry, have invested overUSD 5 billion in capital across 65 instances, in the period between 2014 and2019
· The increasing interest in this field isreflected in recent partnership activity; majority of deals inked were R&Dand licensing agreements, featuring the participation of both international andindigenous stakeholders
· In order to keep patients and healthcareprofessionals informed and aware of the developments in this field of medicine,companies are deploying diverse promotional strategies for their respectiveproducts
· Prevalent trends indicate that the market forRNAi therapeutics is poised to grow significantly as multiple late stagemolecules are commercialized in the near future, for the treatment of differentclinical conditions
TABLEOF CONTENTS
1. PREFACE
1.1. Scopeof the Report
1.2. ResearchMethodology
1.3. ChapterOutlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. HistoricalTrends
3.2.1. Discovery of RNAi
3.2.2. RNAi Therapy Development Efforts
3.3. Mechanismof RNAi
3.3.1. Components of RNAi
3.3.2. Cellular Mechanism
3.4. Typesof RNAi Molecules
3.4.1. siRNA
3.4.2. miRNA
3.4.3. shRNA
3.5. Applicationsof RNAi
3.6. Advantagesand Disadvantages of RNAi
3.7. RegulatoryGuidelines
3.8. FuturePerspectives
4. COMPETITIVE LANDSCAPE
4.1. ChapterOverview
4.2. Marketedand Development Pipeline
4.2.1. Analysis by Type of RNAi Molecule
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Type of Target Gene
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Special Drug Designation
4.2.7. Key Players
4.3. DeveloperLandscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptionsand Key Parameters
5.4. CompetitivenessAnalysis
6. LATE STAGE RNAi THERAPEUTICS
6.1. ChapterOverview
6.2. Onpattro®
6.2.1. Drug Overview
6.2.2. Technology Overview
6.2.3. Current Development Status
6.2.4. Recent Clinical Trial Results
6.3. ARO-AAT
6.3.1. Drug Overview
6.3.2. Technology Overview
6.3.3. Current Development Status
6.3.4. Recent Clinical Trial Results
6.4. Fitusiran
6.4.1. Drug Overview
6.4.2. Technology Overview
6.4.3. Current Development Status
6.4.4. Recent Clinical Trial Results
6.5. Givosiran
6.5.1. Drug Overview
6.5.2. Technology Overview
6.5.3. Current Development Status
6.5.4. Recent Clinical Trial Results
6.6. Inclisiran
6.6.1. Drug Overview
6.6.2. Technology Overview
6.6.3. Current Development Status
6.6.4. Recent Clinical Trial Results
6.7. Lumasiran
6.7.1. Drug Overview
6.7.2. Technology Overview
6.7.3. Current Development Status
6.7.4. Recent Clinical Trial Results
6.8. QPI-1002
6.8.1. Drug Overview
6.8.2. Technology Overview
6.8.3. Current Development Status
6.8.4. Recent Clinical Trial Results
6.9. SYL1001
6.9.1. Drug Overview
6.9.2. Technology Overview
6.9.3. Current Development Status
6.9.4. Recent Clinical Trial Results
6.10. Vigil-EWS
6.10.1. Drug Overview
6.10.2. Technology Overview
6.10.3. Current Development Status
6.10.4. Recent Clinical Trial Results
6.11. Vutrisiran
6.11.1. Drug Overview
6.11.2. Technology Overview
6.11.3. Current Development Status
6.11.4. Recent Clinical Trial Results
Formore information, please click on the following link:
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
